1. Market Research
  2. > Mild Pain - Pipeline Review, H1 2013

Mild Pain - Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 22 pages

Mild Pain - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Mild Pain - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Mild Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mild Pain. Mild Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Mild Pain.
- A review of the Mild Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Mild Pain pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Mild Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Mild Pain pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Mild Pain - Pipeline Review, H1 2013
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Mild Pain Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Mild Pain 6
Mild Pain Therapeutics under Development by Companies 8
Pre-Clinical Stage Products 9
Comparative Analysis 9
Mild Pain Therapeutics - Products under Development by Companies 10
Companies Involved in Mild Pain Therapeutics Development 11
Nektar Therapeutics 11
Immupharma Plc 12
Mild Pain - Therapeutics Assessment 13
Assessment by Monotherapy Products 13
Assessment by Route of Administration 14
Assessment by Molecule Type 16
Drug Profiles 18
NKTR-194 - Drug Profile 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
IPP-102199 - Drug Profile 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Mild Pain Therapeutics - Dormant Products 20
Appendix 21
Methodology 21
Coverage 21
Secondary Research 21
Primary Research 21
Expert Panel Validation 21
Contact Us 22
Disclaimer 22

List of Tables


Number of Products Under Development for Mild Pain, H1 2013 6
Products under Development for Mild Pain - Comparative Analysis, H1 2013 7
Number of Products under Development by Companies, H1 2013 8
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 9
Products under Development by Companies, H1 2013 10
Nektar Therapeutics, H1 2013 11
Immupharma Plc, H1 2013 12
Assessment by Monotherapy Products, H1 2013 13
Assessment by Stage and Route of Administration, H1 2013 15
Assessment by Stage and Molecule Type, H1 2013 17
Mild Pain Therapeutics - Dormant Products 20

List of Figures


Number of Products under Development for Mild Pain, H1 2013 6
Products under Development for Mild Pain - Comparative Analysis, H1 2013 7
Products under Development by Companies, H1 2013 8
Pre-Clinical Stage Products, H1 2013 9
Assessment by Monotherapy Products, H1 2013 13
Assessment by Route of Administration, H1 2013 14
Assessment by Stage and Route of Administration, H1 2013 15
Assessment by Molecule Type, H1 2013 16
Assessment by Stage and Molecule Type, H1 2013 17

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.